Everolimus Plus Octreotide Long-Acting Repeatable (LAR) for the Treatment of Advanced Neuroendocrine Tumors (NET) Associated with Carcinoid Syndrome: Updated Overall Survival Results from RADIANT-2 Study

James C. Yao1; Kjell E. Öberg2; John D. Hainsworth3; Du Lam4; Sotirios G. Stergiopolos4; Nicolas Rouyrre5; Marc Peeters6; Eric Baudin7; David Gross8; and Marianne E. Pavel9

1Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
2Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
3Sarah Cannon Research Institute, Nashville, TN, USA
4Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
5Novartis International AG, Basel, Switzerland
6Department of Oncology, Antwerp University Hospital, Edegem, Belgium
7Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave-Roussy, Villejuif Cedex, France
8Neuroendocrine Tumor Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
9Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin/Campus Virchow Klinikum, Berlin, Germany

Background: Everolimus (E)+octreotide LAR (O) improved median adjudicated central review-assessed progression-free survival (PFS) by 5.1 months versus placebo (P)+O in patients with advanced NET (HR=0.77, 95%CI, 0.59-1.0; one-sided \( P =0.026 \); prespecified \( P \leq 0.0246 \)) in the RADIANT-2 trial (NCT00412061). Updated overall survival (OS) results are presented.

Methods: Patients were randomized to E+O (E, 10mg/d; O, 30mg q28d; n=216) or P+O (O, 30mg q28d; n=213). A total of 170 patients switched over to open-label E+O—143 patients from P+O arm after disease progression; 27 from E+O arm after study unblinding—and were retained for OS analysis. Final OS analysis was planned after 252 events.

Results: As of April 23, 2012, median E exposure was 37.0 weeks (range,1-270) for E+O arm and 34.1 weeks (range,1-200) in patients randomized to P+O who switched to open-label E+O. Kaplan-Meier estimates (95%CI) in the E+O and P+O arms, respectively: 1 year, 80.5% (74.5-85.3) and 81.8% (75.8-86.4); 2 years, 57.0% (49.9-63.4) and 63.6% (56.6-69.8); 3 years, 42.9% (36.0-49.6) and 48.5% (41.4-55.3). After 253 events, the median OS (95%CI) was 29.2 (23.8-35.9) months with E+O and 35.2 (30.0-44.7) months with P+O (HR=1.16, 95% CI, 0.91-1.49). Adjusted for baseline covariates (age, sex, race, WHO PS, prior somatostatin analog [SSA]), HR was 1.06 (95%CI, 0.82-1.36). Adverse events (AEs) reported during the open-label phase (n=170) were consistent with those observed during blinded treatment. On-treatment deaths were observed in 8.8% in the E+O and 5.2% in the P+O arm in the blinded phase and 12.9% in the open-label phase.

Conclusions: There was no significant difference in OS between E+O and P+O arms, even after adjusting for imbalances in baseline covariates. Likelihood of detecting OS differences might have been confounded by crossover to E+O, imbalanced informative censoring, unknown therapy after study end, and imbalance in other baseline characteristics that could not be adjusted.

Supported by Novartis Pharmaceuticals Corporation.